Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Non-Current Debt (2020 - 2025)

Historic Non-Current Debt for Aytu Biopharma (AYTU) over the last 6 years, with Q4 2025 value amounting to $10.0 million.

  • Aytu Biopharma's Non-Current Debt rose 15.03% to $10.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $10.0 million, marking a year-over-year increase of 15.03%. This contributed to the annual value of $10.9 million for FY2025, which is 16.55% up from last year.
  • Aytu Biopharma's Non-Current Debt amounted to $10.0 million in Q4 2025, which was up 15.03% from $10.4 million recorded in Q3 2025.
  • In the past 5 years, Aytu Biopharma's Non-Current Debt registered a high of $15.0 million during Q4 2023, and its lowest value of $129000.0 during Q4 2021.
  • Over the past 5 years, Aytu Biopharma's median Non-Current Debt value was $10.9 million (recorded in 2024), while the average stood at $10.3 million.
  • Its Non-Current Debt has fluctuated over the past 5 years, first plummeted by 9870.29% in 2021, then surged by 1116589.15% in 2022.
  • Aytu Biopharma's Non-Current Debt (Quarter) stood at $129000.0 in 2021, then surged by 11165.89% to $14.5 million in 2022, then grew by 3.06% to $15.0 million in 2023, then crashed by 33.35% to $10.0 million in 2024, then rose by 0.15% to $10.0 million in 2025.
  • Its last three reported values are $10.0 million in Q4 2025, $10.4 million for Q3 2025, and $10.9 million during Q2 2025.